Jardiance® is the First Type 2 Diabetes Medication to Significantly Reduce Risk of Cardiovascular Complications and Death
News
Type II diabetes medication Jardiance® (empagliflozin) by Boehringer Ingelheim and Eli Lilly and Company, recently became the first of its kind to demonstrate a significantly lowered risk of cardiovascular risk and death, ... Read more